First BE Study for Extended Release Molecule Completed by KDU & CIC
CIC Holdings PLC successfully completed the Bioequivalence (BE) study on Metformin Extended-Release as the first BE for an extended-release molecule in Sri Lanka by The Institute for Combinatorial Advanced Research and Education (KDU-CARE) of General Sir John Kotelawala Defense University (KDU).
The final report was handed over by the Vice-Chancellor of KDU Major General Milinda Peiris to Mr. Aroshan Seresinhe, Group Chief Executive Officer of CIC Holdings PLC, Mr. Viraj Manatunga – Divisional Director of Health Care, Mr. Thilak Haputhathri – Head of Regulatory Affairs, and Mr.Sanjaya Rathnayake – Business Development Manager.
Prof. Thushara Weerawardane – Director, KDU-CARE, Snr. Prof Rohini Fernandopulle – WHO National Consultant on Regulatory Functions to NMRA, Prof. Charitha Gunasekara – Former Acting Director, KDU-CARE, Dr. Himali Jayasinghearachchi, Principal Investigator, and Dr. Pandula Athauda-arachchi, Consultant Interventional Cardiologist (UK & SL Board Certified) participated in this historic occasion.